Tremfya (guselkumab) / J&J 
Welcome,         Profile    Billing    Logout  
 11 Diseases   38 Trials   38 Trials   2772 News 


«12...27282930313233343536373839»
  • ||||||||||  Journal:  Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. (Pubmed Central) -  Aug 23, 2020   
    Risankizumab is a newly FDA-approved IL-23 inhibitor that shows particular promise in the treatment of plaque psoriasis. Based on this review, it is an effective and safe addition to the armamentarium of biologics that are currently available.
  • ||||||||||  Tremfya (guselkumab) / J&J
    Clinical, Journal:  Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient. (Pubmed Central) -  Aug 22, 2020   
    We read with great interest the publication of Messina et al reporting the first case of SARS-CoV2 infection in a young patient of 32-year-old suffering from psoriasis and psoriatic arthritis treated by Guselkumab, a monoclonal antibody that targets specifically the p19 subunit of Interleukin (IL)-23 .The patient contracted the SARS-CoV2 infection after a dinner with some friends but fortunately she developed very discrete symptoms including only mild fever and rhinorrhea. These findings support the potential role of IL-23p19 inhibitors to counteract the « cytokine storm » triggered by the SARS-CoV2 and which is potentially implicated in the severity of the symptoms .
  • ||||||||||  Tremfya (guselkumab) / J&J
    Trial completion date, Trial primary completion date:  A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants (clinicaltrials.gov) -  Aug 19, 2020   
    P1,  N=568, Recruiting, 
    These findings support the potential role of IL-23p19 inhibitors to counteract the « cytokine storm » triggered by the SARS-CoV2 and which is potentially implicated in the severity of the symptoms . Trial completion date: Jul 2020 --> Sep 2021 | Trial primary completion date: Jul 2020 --> Sep 2021
  • ||||||||||  Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
    [VIRTUAL] Guselkumab use in chronic plaque psoriasis: real‐world data suggest Psoriasis Area and Severity Index (PASI75) response takes longer than 16 weeks () -  Aug 12, 2020 - Abstract #BAD2020BAD_5;    
    The majority (n = 28; 61%) had tried two prebiological systemic agents, most commonly methotrexate (n = 43; 95%) and 34 (74%) of patients had trialled phototherapy...However, initial results show guselkumab as a promising, well‐tolerated agent in treatment‐resistant psoriasis. These results suggest it may be prudent to persist beyond 16 weeks even if initial scores do not reach PASI50, as proportionally more than twice as many patients achieved PASI75 at extended follow‐up, meaning the current license may prematurely dismiss potential responders.
  • ||||||||||  Prezcobix (darunavir/cobicistat) / Gilead, J&J, Tremfya (guselkumab) / J&J
    [VIRTUAL] Successful treatment of psoriasis with guselkumab in an individual with HIV–hepatitis B virus co‐infection () -  Aug 12, 2020 - Abstract #BAD2020BAD_2;    
    Oral methotrexate 25 mg was prescribed once weekly for 6 months with minimal improvement...Current biological therapies for use in HIV‐positive patients with psoriasis: case report of guselkumab used and review. Dermatol Online J 2018; 24). The majority of cases reported excellent clinical responses, limited adverse events and stable CD4 counts and viral loads throughout treatment. Guselkumab is the first approved biological therapy that selectively blocks interleukin 23. We report the second case of successful treatment of psoriasis with guselkumab in a HIV‐infected individual.
  • ||||||||||  Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Enbrel (etanercept) / Pfizer, Amgen, Tremfya (guselkumab) / J&J
    Journal:  A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab. (Pubmed Central) -  Aug 9, 2020   
    Limitations included the limited number of publications, imputation of placebo arm values for Weeks 24 to 28, and limited relevance of the Japanese study. This indirect comparison does not provide evidence that one treatment is superior to the other.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
    Clinical, Journal:  Pharmacological Management of Pediatric Pustular Psoriasis. (Pubmed Central) -  Jul 29, 2020   
    More recently, secukinumab, ixekizumab, brodalumab, guselkumab, and risankizumab have been approved for adult pustular psoriasis in selected countries. Controlled studies are needed to prove the efficacy and long-term safety of the therapeutic treatments currently used for JPP.
  • ||||||||||  Stelara (ustekinumab) / J&J
    Clinical, PK/PD data, Journal:  Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies. (Pubmed Central) -  Jul 22, 2020   
    IL-23 pharmacokinetic parameters along with clinical drug exposure and IL-23 binding affinities from four different anti-IL-23 antibodies (ustekinumab, tildrakizumab, guselkumab, and risankizumab) were used to build a pharmacokinetics/pharmacodynamics (PK/PD) model to assess the time course of free IL-23 over one year in psoriasis patients following different dosing regimens. The predicted rank order of reduction of free IL-23 was consistent with their reported rank order of Psoriasis Area and Severity Index (PASI) 100 scores in clinical efficacy trials (ustekinumab < tildrakizumab < guselkumab < risankizumab), thus demonstrating the utility of highly sensitive AMS for determining target pharmacokinetics to inform PK/PD modeling and assessing target suppression associated with clinical efficacy.
  • ||||||||||  Cosentyx (secukinumab) / Novartis
    Trial completion, Head-to-Head:  ARROW: Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab (clinicaltrials.gov) -  Jul 20, 2020   
    P2,  N=40, Completed, 
    The predicted rank order of reduction of free IL-23 was consistent with their reported rank order of Psoriasis Area and Severity Index (PASI) 100 scores in clinical efficacy trials (ustekinumab < tildrakizumab < guselkumab < risankizumab), thus demonstrating the utility of highly sensitive AMS for determining target pharmacokinetics to inform PK/PD modeling and assessing target suppression associated with clinical efficacy. Active, not recruiting --> Completed
  • ||||||||||  Tremfya (guselkumab) / J&J
    Journal:  IL-23 inhibitor guselkumab shows promise for PsA. (Pubmed Central) -  Jul 16, 2020   
    Through Wk 12, GUS demonstrated a safety profile consistent with that established from clinical trials across investigational and approved indications. No abstract available
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Review, Journal:  Small Molecules and Biologics in the Treatment of Nail Psoriasis. (Pubmed Central) -  Jul 15, 2020   
    Introduction of biologics and small molecules in the treatment of nail PsO has allowed for rapid control of the disease and high efficacy. The aim of this review was to present the published studies on nail PsO therapy with biologics and small molecules and illuminate the results in the studies where the design and outcome evaluation had nail PsO in the forefront.
  • ||||||||||  Stelara (ustekinumab) / J&J
    [VIRTUAL] Psoriasis patient serum biomarkers may be useful for separating response to therapy endotypes () -  Jul 1, 2020 - Abstract #SID2020SID_45;    
    Five of the eleven patients who previously tried ustekinumab were started on guselkumab, achieving clear/almost clear results. Among Responders, hs-CRP values were significantly lower (median 1.5 vs. 7.1, p=0.0381) compared to Non-responding patients, suggesting that serum protein values may be useful as potential biomarkers for separating psoriasis patient endotypes.
  • ||||||||||  Hutruo (bermekimab IV) / J&J, Humira (adalimumab) / Eisai, AbbVie
    Review, Journal:  Pharmacological development in hidradenitis suppurativa. (Pubmed Central) -  Jun 26, 2020   
    In recent years, new phase II and III trials for HS management have appeared aimed at inhibition of specific targetable inflammatory pathways identified in HS. Thus, several new biologics are being investigated, including MABp1 (bermekimab), CJM112, bimekizumab, guselkumab, secukinumab, and IFX-1.
  • ||||||||||  Biomarker, Review, Journal:  State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. (Pubmed Central) -  Jun 26, 2020   
    The availability of biosimilars at much lower cost compared to originators is dramatically changing the access of patients to these treatments. In the coming years, studies will progress to identify subgroups of patients based on biomarkers for a more personalized treatment approach.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
    Journal, Head-to-Head:  Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate to severe plaque psoriasis. (Pubmed Central) -  Jun 19, 2020   
    The NNT for a PASI 90 response was 1.3 for guselkumab and 2.1 for adalimumab; CPRs and NNT were also lower for guselkumab than for adalimumab for PASI 75 and PASI 100 for both induction and maintenance years. Limitations and In this analysis, extrapolating 48-week results from a single head-to-head study, guselkumab was more cost-effective with lower NNT than adalimumab in both the induction and maintenance years for PASI 75, PASI 90, and PASI 100 responses.
  • ||||||||||  Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
    Clinical, Journal:  Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. (Pubmed Central) -  Jun 15, 2020   
    Guselkumab has also been shown to be superior to secukinumab in PASI90 response rate at week 48 in a head-to-head trial (ECLIPSE); it is also successful in treating patients with incomplete responses to adalimumab (VOYAGE 2) and ustekinumab (NAVIGATE). Guselkumab may be effective in treating psoriatic arthritis, with several phase III trials ongoing, and a clinical research program in Crohn's disease is underway.
  • ||||||||||  Retrospective data, Review, Journal:  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (Pubmed Central) -  Jun 14, 2020   
    Living systematic reviews offer a new approach to review updating, in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
  • ||||||||||  Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen
    Review, Journal:  Interventions for chronic palmoplantar pustulosis. (Pubmed Central) -  Jun 14, 2020   
    Reporting of serious adverse effects was incomplete: compared to placebo, secukinumab probably caused more participant withdrawals (moderate-quality evidence), but we are uncertain of the effect of guselkumab (low-quality evidence). Future trials should assess commonly used treatments using validated severity and quality of life scales.